1-5 of 5
Lesa Gardner, RN
Close
Sort by
Journal Articles

Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial

Paul G. Richardson, MD, Jeffrey Lee Wolf, MD, Andrzej J. Jakubowiak, MD, PhD, Jeffrey A. Zonder, MD, Sagar Lonial, MD, David Irwin, MD, John Densmore, MD, PhD, Amrita Krishnan, MD, Noopur S. Raje, MD, Michael H. Bar, MD, Robert Schlossman, MD, Irene M. Ghobrial, MD, Nikhil C. Munshi, MD, Thomas Martin, MD, Jacob P. Laubach, MD, Jeffrey P Allerton, MD, Teru Hideshima, MD, PhD, Peter Sportelli, Lesa Gardner, RN, Kenneth C. Anderson, MD
Journal: Blood
Blood (2011) 118 (21): 815.
https://doi.org/10.1182/blood.V118.21.815.815
Published: 2011
Journal Articles

Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)

Andrzej J Jakubowiak, MD, PhD, Paul G Richardson, MD, Todd M Zimmerman, MD, Melissa Alsina, MD, Jonathan L. Kaufman, MD, Malathi Kandarpa, PhD, Colleen K. Harvey, Kathleen Colson, RN, BSN, BS, Monica Mitchell, RN, OCN, Teru Hideshima, MD, PhD, Peter Sportelli, Lesa Gardner, RN, Kathy Giusti, MBA, Kenneth C. Anderson, MD
Journal: Blood
Blood (2010) 116 (21): 3064.
https://doi.org/10.1182/blood.V116.21.3064.3064
Published: 2010
Journal Articles

Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results.

Paul Richardson, M.D., Ph.D., Jeffrey Lee Wolf, MD, Andrzej Jakubowiak, MD, PhD, Jeffrey A. Zonder, MD, Sagar Lonial, MD, David H Irwin, MD, Amrita Krishnan, MD, John Densmore, MD, PhD, Noopur Raje, MD, Michael H. Bar, MD, Robert L Schlossman, M.D., Ph.D., Irene Ghobrial, MD, Nikhil C. Munshi, MD, Thomas Martin, MD, Jacob Laubach, MD, Jeffrey P. Allerton, MD, Teru Hideshima, MD, PhD, Lesa Gardner, RN, Peter Sportelli, Kenneth C. Anderson, MD
Journal: Blood
Blood (2009) 114 (22): 1869.
https://doi.org/10.1182/blood.V114.22.1869.1869
Published: 2009
Journal Articles

Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib

Paul Richardson, MD, Jeffrey Wolf, MD, Andrzej Jakubowiak, MD, PhD, Jeffrey Zonder, MD, Sagar Lonial, MD, David H Irwin, MD, John Densmore, MD, PhD, Amrita Krishnan, MD, FACP, Noopur Raje, MD, Michael H. Bar, MD, Jeffrey P. Allerton, MD, Robert Schlossman, Irene M. Ghobrial, M.D., Nikhil C. Munshi, MD, Thomas Martin, MD, Jacob Laubach, MD, Kathy Colson, RN, Sarah Dean, Deanna Tocco, Elizabeth Steinfield, RN, Tara Kendall, PA, Kimberly O’Riley, RN, Teru Hideshima, MD, PhD, Peter Sportelli, Lesa Gardner, RN, Kenneth C. Anderson, MD
Journal: Blood
Blood (2008) 112 (11): 870.
https://doi.org/10.1182/blood.V112.11.870.870
Published: 2008
Journal Articles

Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

Andrzej Jakubowiak, MD, PhD, Paul Richardson, MD, Todd M. Zimmerman, MD, Melissa Alsina, MD, Jonathan L. Kaufman, MD, Colleen Harvey, Christine Brozo, PA, Tara Kendall, PA, Amanda McAllister, Teru Hideshima, MD, PhD, Peter Sportelli, Lesa Gardner, RN, Kenneth C. Anderson, MD, Kathy Giusti, MBA
Journal: Blood
Blood (2008) 112 (11): 3691.
https://doi.org/10.1182/blood.V112.11.3691.3691
Published: 2008